EU/3/09/670: Orphan designation for the treatment of acromegaly

pasireotide

Overview

On 8 October 2009, orphan designation (EU/3/09/670) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for pasireotide for the treatment of acromegaly.

Pasireotide in treatment of acromegaly has been authorised in the EU as Signifor since 19 November 2014.

The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.

The sponsorship was transferred to Recordati Rare Diseases, France in May 2020.

Key facts

Active substance
pasireotide
Medicine name
Signifor
Intended use
Treatment of acromegaly
Orphan designation status
Positive
EU designation number
EU/3/09/670
Date of designation
08/10/2009
Sponsor

Recordati Rare Diseases   
Immeuble Le Wilson
70 Avenue Du General De Gaulle
92800 Puteaux
France
Tel. +33 1 4773 9527
E-mail: RRDinfo@recordati.com

Review of designation

During its meeting of 7 to 9 October 2014, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/09/670 for Signifor (pasireotide) as an orphan medicinal product for the treatment of acromegaly. The COMP assessed whether, at the time of addition of a new indication to the marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other methods of treatment. As other methods of treatment are authorised in the European Union (EU), the COMP also considered whether the medicine is of significant benefit to patients with acromegaly. The COMP recommended that the orphan designation of the medicine be maintained*.


*The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with a comparable therapeutic indication cannot be placed on the market.

Documents related to this orphan designation evaluation

  • List item

    Recommendation for maintenance of orphan designation at the time of marketing authorisation: Signifor (pasireotide) for the treatment of acromegaly (PDF/79.15 KB)

    Adopted

    First published: 21/01/2015
    Last updated: 21/01/2015
    EMA/COMP/621067/2014

  • Patients' organisations

    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

    • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

    • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

    EU register of orphan medicines

    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

    Related content

    How useful was this page?

    Add your rating
    Average
    2 ratings
    1 rating